Sunday, January 18, 2015
NeuroDerm ($NDRM) appears to be drifting downward. I suspect 2 reasons: 1. the apparent absence of a near term positive catalyst and 2. the end of the IPO lockup period will expire in mid-May and possibly cause a flow of new shares, diluting the existing shares being traded currently. The stock will stabilize eventually as the longer term investment thesis is solid, but the short term forecast may be problematic. The results of a trial that draw a comparison between the proposed NeuroDerm therapy and the Duodopa approach (recently approved for Abbvie by the FDA) is likely in 2015, but I have yet to find information on exactly when this information might become available from NeuroDerm.